|Bid||66.95 x 900|
|Ask||66.96 x 800|
|Day's Range||66.26 - 67.47|
|52 Week Range||56.56 - 85.97|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||66.47|
|Earnings Date||Feb. 04, 2021|
|Forward Dividend & Yield||2.72 (4.06%)|
|Ex-Dividend Date||Dec. 14, 2020|
|1y Target Est||72.85|
Last year, Sorrento Therapeutics (NASDAQ: SRNE) became one of the hottest coronavirus stocks. The enormous volatility behind Sorrento stock is not without reason. After the development of its coronavirus tests and therapeutics began to stall, shareholders started ditching the company in favor of its competitors.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s fourth quarter and full year 2020 financial results and will provide a business update.
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.